PeptiDream Inc represents values of innovation, collaboration, and excellence in the field of peptide therapeutics. The company's corporate philosophy revolves around utilizing its proprietary Peptide Discovery Platform System (PDPS) to develop novel and optimized peptides for drug discovery and development. By leveraging their cutting-edge technology and expertise, PeptiDream Inc aims to advance therapeutic options for various diseases, including cancer, metabolic disorders, and autoimmune conditions. The company emphasizes the importance of partnerships with biopharmaceutical companies, academia, and other stakeholders to accelerate the translation of discoveries into potential life-saving treatments. PeptiDream Inc's commitment to scientific advancement and breakthrough innovation drives its mission to improve global healthcare.

PeptiDream Inc is primarily present in Japan and the United States.

PeptiDream Inc has achieved several significant milestones. The company has successfully developed a unique peptide discovery platform called PDPS (Peptide Discovery Platform System), which enables the rapid and efficient discovery of highly diverse and functional peptide-based therapeutics. PeptiDream Inc has also established numerous collaborations with leading pharmaceutical companies to advance the development of novel peptides for various therapeutic areas. Additionally, the company has received multiple prestigious awards and recognitions for its innovative approaches and contributions to the field of peptide-based drug discovery. PeptiDream Inc continues to make remarkable progress in the discovery and development of peptide therapeutics, solidifying its position as a prominent player in the industry.

PeptiDream Inc. is a renowned Japanese biopharmaceutical company specializing in peptide drug discovery and development. Founded in 2006, the company has established itself as a leader in the discovery and development of non-standard peptide therapeutics. PeptiDream employs its unique and proprietary Peptide Discovery Platform System (PDPS) to create a diverse library of potential drug candidates. This platform enables the rapid and efficient identification and optimization of peptide-based drugs. PeptiDream has entered into numerous partnerships with leading pharmaceutical companies globally, leveraging its expertise to explore applications in various therapeutic areas. With its innovative approach and extensive collaborations, PeptiDream continues to make significant contributions to the field of peptide drug discovery and development.

The main competitors of PeptiDream Inc in the market include Zai Lab Limited, AstraZeneca PLC, and Novartis AG.

PeptiDream Inc is primarily active in the pharmaceutical industry.

PeptiDream Inc's business model revolves around peptide drug discovery and development. The company utilizes its proprietary Peptide Discovery Platform System (PDPS) to create a wide range of non-standard peptide libraries. These libraries serve as valuable sources for identifying potential drug candidates. PeptiDream collaborates with pharmaceutical and biotech companies, enabling them to access its renowned libraries. This business model allows PeptiDream to generate revenue through licensing and milestone payments. By leveraging their expertise in peptide-based therapeutics, PeptiDream Inc aims to contribute to the development of innovative drugs and enhance treatments for various diseases.

مُعامل القيمة السوقية إلى الأرباح لـ PeptiDream هو ٤٢٫٧٩.

مُعامِل القيمة إلى المبيعات PeptiDream هو ٨٫٦٧.

نقاط جودة AlleAktien لـ PeptiDream هي 5/10.

المتوقعة PeptiDream الإيرادات هي ٣٧٫٥٧ مليارات JPY.

صافي الربح المتوقعة PeptiDream هو ٧٫٦٢ مليارات JPY.

The company PeptiDream Inc. is a biopharmaceutical company from Japan specialized in the discovery and development of peptide drug candidates. The company was founded in 2006 and is headquartered in Kawasaki City, Japan. PeptiDream utilizes a proprietary technology platform called Peptide Discovery Platform System (PDPS) to create and optimize specific peptide libraries used for the search of new peptide drug candidates. These peptides offer several advantages over traditional small molecules and proteins, including higher selectivity, efficacy, and stability. The company operates in three business areas: 1. Research and Development: PeptiDream collaborates with multinational pharmaceutical companies to develop new peptide drug candidates for various therapeutic applications. The company has partnerships with leading pharmaceutical companies such as Eli Lilly, Novartis, and Sanofi. 2. Standalone project business: PeptiDream also develops its own peptide drug candidates and conducts pre-clinical and clinical studies to test their efficacy and safety. The company has several programs for the development of peptide drug candidates in the areas of oncology, anti-allergy, and metabolism. 3. Platform technology: PeptiDream also offers its PDPS technology platform as a service. Companies can utilize this platform to quickly and effectively create and optimize their own peptide libraries. PeptiDream has a wide range of products utilized both for partnerships and its own development programs. Some of the products include: 1. PDPS technology: Peptide Discovery Platform System (PDPS) is a proprietary technology platform by PeptiDream. It is a fast and effective method for the creation and optimization of peptide libraries. 2. Peptide drug candidates: PeptiDream has created an extensive peptide library with potential drug candidates for various therapeutic applications. These peptides are used for drug development. 3. Peptides for partners: PeptiDream collaborates with multinational pharmaceutical companies to develop new peptide drug candidates for various therapeutic applications. The company also provides its partners with access to its peptide library and PDPS technology platform. Overall, PeptiDream is an innovative company developing peptide drug candidates for a wide range of therapeutic applications. The company has utilized its PDPS technology platform as a key to success and has established itself as a preferred partner for multinational pharmaceutical companies.

يوزع PeptiDream أرباحًا قدرها 0 JPY من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ PeptiDream في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـPeptiDream هو JP3836750004.

رمز WKN لـ PeptiDream هو A1W0KK.

الرمز المُختصر لـ PeptiDream هو 4587.T.

خلال آخر 12 شهراً، دفعت PeptiDream توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع PeptiDream خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 JPY.

نسبة توزيعات الأرباح الحالية لـ PeptiDream هي .

PeptiDream يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

PeptiDream دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 JPY. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

PeptiDream يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 JPY من PeptiDream المُعلن عنها في ٩‏/٧‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٩‏/٧‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٩‏/٧‏/٢٠٢٤.

في العام 2023، وزعت PeptiDream 0 JPY كأرباح أسهم.

يتم توزيع أرباح PeptiDream بالعملة JPY.